Ivax Corporation Receives Marketing Authorization and Tentative FDA Approval for Two Key Products

Strategic Insights -

Ivax Corporation, a leading pharmaceutical company, has received significant regulatory approvals for its two key products: fluticasone nasal spray and levofloxacin tablets. The company's fluticasone nasal spray has been granted final marketing authorization by the U.K. Medicine and Healthcare Products Regulatory Agency, while its levofloxacin tablets have received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) in three dosage strengths. These approvals mark a significant milestone for Ivax, allowing the company to bring these essential products to market and capitalize on the growing demand for affordable generic medications.

Key Takeaways:

  • Ivax Corporation's fluticasone nasal spray has received final marketing authorization from the U.K. Medicine and Healthcare Products Regulatory Agency, making it the first generic equivalent of Flixonase/Flonase available in the U.K. market.
  • The product, developed by Ivax Research, Inc., is expected to challenge the dominance of GlaxoSmithKline's Flixonase in the U.K. market, where annual sales are approximately $30 million.
  • Ivax plans to aggressively pursue approvals for this product across Europe and has an ANDA pending with the U.S. FDA.
  • Levofloxacin tablets, the generic equivalent of Levaquin Tablets, a quinolone antibiotic, has received tentative FDA approval for its ANDA in three dosage strengths (250, 500, and 750 mg).
  • According to IMS data, U.S. sales for Levaquin Tablets in 2005 reached $1.2 billion for the 12 months ended March 31, 2005.
  • Ivax' levofloxacin tablets are expected to be a significant player in the market, with the potential to disrupt current market leaders.

Statistics:

  • U.S. sales for Levaquin Tablets in 2005: $1.2 billion for the 12 months ended March 31, 2005 (Source: IMS data).
  • Annual U.K. sales of Flixonase: approximately $30 million (no specific date mentioned).
  • Dosage strengths for levofloxacin tablets: 250, 500, and 750 mg.

Sources:

  • Health & Medicine Week editors (2005).
  • NewsRx.com.